Mohammad Kawsar Sharif Siam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mohammad Kawsar Sharif Siam has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Eva Rahman Kabir
School of Pharmacy BRAC University Dhaka Bangladesh
7 shared publications - Mohammad Umer Sharif Shohan
European Molecular Biology Laboratory European Bioinformatics Institute (EMBL‐EBI) Wellcome Genome Campus Hinxton, Cambridge UK
3 shared publications Nashrah Mustafa
Department of Pharmacy, BRAC University, Bangladesh
3 shared publications- Samiul Alam Rajib
Division of Genomics and Transcriptomics Joint Research Center for Human Retrovirus Infection Kumamoto University Kumamoto Japan
3 shared publications Mohammad Umer Sharif Shohan
2 shared publicationsSanam Madihah Kabir
Eva Kabir Lab, Department of Pharmacy, BRAC University, Dhaka Bangladesh
2 shared publications
Latest Publications
- 15 April 2023
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 159, 106944
Transcriptomic analysis of esophageal cancer reveals hub genes and networks involved in cancer progression
- 15 April 2023
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 159, 106944
Transcriptomic analysis of esophageal cancer reveals hub genes and networks involved in cancer progression
- Open Access
- 1 February 2021
- Published by Elsevier in Translational Oncology
- Vol. 14 (2) , 100995
Extracellular heat shock proteins and cancer: New perspectives
- 1 February 2021
- Published by Elsevier in Translational Oncology
- Vol. 14 (2) , 100995
Open AccessExtracellular heat shock proteins and cancer: New perspectives
- Open Access
- 18 August 2020
- Published by Wiley
Onset, Transmission, Impact, and Management of COVID-19 Epidemic at Early Stage in SAARC Countries
The impact of the COVID-19 outbreak had devastating consequences globally with 20,675,770 affected and 749,061 dead. Despite different measures to restrict transmission, the death toll continues to rise. The SAARC group of countries comprising eight nations—Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan and Sri Lanka, where 23.75% of the world population reside, implemented containment measures at different stages of the outbreak with varying consequences. In this review, we examined the onset and transmission of the virus in each country at an early stage and critically appraised their response with respect to their medical facilities for diagnosis and management. We found that countries that succeeded to contain the spread of COVID-19 were able to do so by prioritizing non-pharmaceutical interventions (e.g. early and stricter lockdowns). Currently, the epicentre of COVID-19 appears to be shifting to India (the largest SAARC nation), the death toll is likely to steeply increase if effective and aggressive measures are not taken urgently. The authors believe that authorities of each of the SAARC countries should act decisively and cooperatively as a matter of urgency increasing the regional collaboration in an eloquent and durative way.
- 18 August 2020
- Published by Wiley
Open AccessOnset, Transmission, Impact, and Management of COVID-19 Epidemic at Early Stage in SAARC Countries
The impact of the COVID-19 outbreak had devastating consequences globally with 20,675,770 affected and 749,061 dead. Despite different measures to restrict transmission, the death toll continues to rise. The SAARC group of countries comprising eight nations—Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan and Sri Lanka, where 23.75% of the world population reside, implemented containment measures at different stages of the outbreak with varying consequences. In this review, we examined the onset and transmission of the virus in each country at an early stage and critically appraised their response with respect to their medical facilities for diagnosis and management. We found that countries that succeeded to contain the spread of COVID-19 were able to do so by prioritizing non-pharmaceutical interventions (e.g. early and stricter lockdowns). Currently, the epicentre of COVID-19 appears to be shifting to India (the largest SAARC nation), the death toll is likely to steeply increase if effective and aggressive measures are not taken urgently. The authors believe that authorities of each of the SAARC countries should act decisively and cooperatively as a matter of urgency increasing the regional collaboration in an eloquent and durative way.
- 4 August 2020
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 39 (17) , 6467-6479
In silicodrug design and molecular docking studies targeting Akt1 (RAC-alpha serine/threonine-protein kinase) and Akt2 (RAC-beta serine/threonine-protein kinase) proteins and investigation of CYP (cytochrome P450) inhibitors against MAOB (monoamine oxidase B) for OSCC (oral squamous cell carcinoma) treatment
The overexpression of Akt1 (RAC-alpha serine/threonine-protein Kinase) and Akt2 (RAC-beta serine/threonine-protein Kinase) is a hallmark of Oral Squamous Cell Carcinoma (OSCC). Because of the elevated frequency of OSCC occurrence in South Asian countries, novel therapeutic approaches are indispensable. Drugs that inhibit the overexpression of Akt1 and Akt2 proteins in Akt pathway and do not cause reduced expression of MAOB can be leads for OSCC treatment. In this study, Akt1, Akt2 and MAOB were targeted and 100 CYP inhibitors were screened through several in silico approaches and Galuteolin and Linarin were identified as potential leads for OSCC treatment as they inhibited Akt1 proteins with strong binding affinities of −12.3 and −11.5 kcal/mol respectively and also Akt2 proteins with strong binding affinities of −11.4 and −11.1 kcal/mol respectively, but they did not inhibit MAOB. Decreased expression of MAOB in tissues causes OSCC but overexpression is also responsible for other types of diseases and cancers. From the investigation of CYP inhibitors against MAOB, five CYP inhibitors- Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin have expressed inhibitory action against MAOB without any interference with Akt1 and Akt2. This study mainly represents that Galuteolin and Linarin in the Akt pathway can be perceived for OSCC treatment and other five CYP inhibitors – Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin for the treatment of other diseases and cancers caused by overexpression of MAOB. ADMET properties of CYP inhibitors obtained from admetSAR 2.0 and were compared with reference drugs for validation. Communicated by Ramaswamy H. Sarma.
- 4 August 2020
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 39 (17) , 6467-6479
In silicodrug design and molecular docking studies targeting Akt1 (RAC-alpha serine/threonine-protein kinase) and Akt2 (RAC-beta serine/threonine-protein kinase) proteins and investigation of CYP (cytochrome P450) inhibitors against MAOB (monoamine oxidase B) for OSCC (oral squamous cell carcinoma) treatment
The overexpression of Akt1 (RAC-alpha serine/threonine-protein Kinase) and Akt2 (RAC-beta serine/threonine-protein Kinase) is a hallmark of Oral Squamous Cell Carcinoma (OSCC). Because of the elevated frequency of OSCC occurrence in South Asian countries, novel therapeutic approaches are indispensable. Drugs that inhibit the overexpression of Akt1 and Akt2 proteins in Akt pathway and do not cause reduced expression of MAOB can be leads for OSCC treatment. In this study, Akt1, Akt2 and MAOB were targeted and 100 CYP inhibitors were screened through several in silico approaches and Galuteolin and Linarin were identified as potential leads for OSCC treatment as they inhibited Akt1 proteins with strong binding affinities of −12.3 and −11.5 kcal/mol respectively and also Akt2 proteins with strong binding affinities of −11.4 and −11.1 kcal/mol respectively, but they did not inhibit MAOB. Decreased expression of MAOB in tissues causes OSCC but overexpression is also responsible for other types of diseases and cancers. From the investigation of CYP inhibitors against MAOB, five CYP inhibitors- Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin have expressed inhibitory action against MAOB without any interference with Akt1 and Akt2. This study mainly represents that Galuteolin and Linarin in the Akt pathway can be perceived for OSCC treatment and other five CYP inhibitors – Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin for the treatment of other diseases and cancers caused by overexpression of MAOB. ADMET properties of CYP inhibitors obtained from admetSAR 2.0 and were compared with reference drugs for validation. Communicated by Ramaswamy H. Sarma.
- Open Access
Investigation of the anti-TB potential of selected alkaloid constituents using molecular docking approach
Mycobacterium tuberculosis , the leading bacterial killer disease worldwide, causes Human tuberculosis (TB). Due to the growing problem of drug resistant Mycobacterium tuberculosis strains, new anti-TB drugs are urgently needed. Natural sources such as plant extracts have long played an important role in tuberculosis management and can be used as a template to design new drugs. A wide screening of natural sources is time consuming but the process can be significantly sped up using molecular docking. In this study, we used a molecular docking approach to investigate the interactions between selected natural constituents and three proteins MtPanK, MtDprE1 and MtKasA involved in the physiological functions of Mycobacterium tuberculosis which are necessary for the bacteria to survive and cause disease. The molecular docking score, a score that accounts for the binding affinity between a ligand and a target protein, for each protein was calculated against 150 chemical constituents of different classes to estimate the binding free energy. The docking scores represent the binding free energy. The best docking scores indicates the highest ligand protein binding which is indicated by the lowest energy value. Among the natural constituents, Shermilamine B showed a docking score of - 8.5kcal/mol, Brachystamide B showed a docking score of −8.6 kcal/mol with MtPanK, Monoamphilectine A showed a score of −9.8kcal/mol with MtDprE1.These three compounds showed docking scores which were superior to the control inhibitors and represent the opportunity of in vitro biological evaluation and anti-TB drug design. Consequently, all these compounds belonged to the alkaloid class. Specific interactions were studied to further understand the nature of intermolecular bonds between the most active ligands and the protein binding site residues which proved that among the constituents monoamphilectine A and Shermilamine B show more promise as Anti-TB drugs. Furthermore, the ADMET properties of these compounds or ligands showed that they have no corrosive or carcinogenic parameters. Graphical
Open AccessInvestigation of the anti-TB potential of selected alkaloid constituents using molecular docking approach
Mycobacterium tuberculosis , the leading bacterial killer disease worldwide, causes Human tuberculosis (TB). Due to the growing problem of drug resistant Mycobacterium tuberculosis strains, new anti-TB drugs are urgently needed. Natural sources such as plant extracts have long played an important role in tuberculosis management and can be used as a template to design new drugs. A wide screening of natural sources is time consuming but the process can be significantly sped up using molecular docking. In this study, we used a molecular docking approach to investigate the interactions between selected natural constituents and three proteins MtPanK, MtDprE1 and MtKasA involved in the physiological functions of Mycobacterium tuberculosis which are necessary for the bacteria to survive and cause disease. The molecular docking score, a score that accounts for the binding affinity between a ligand and a target protein, for each protein was calculated against 150 chemical constituents of different classes to estimate the binding free energy. The docking scores represent the binding free energy. The best docking scores indicates the highest ligand protein binding which is indicated by the lowest energy value. Among the natural constituents, Shermilamine B showed a docking score of - 8.5kcal/mol, Brachystamide B showed a docking score of −8.6 kcal/mol with MtPanK, Monoamphilectine A showed a score of −9.8kcal/mol with MtDprE1.These three compounds showed docking scores which were superior to the control inhibitors and represent the opportunity of in vitro biological evaluation and anti-TB drug design. Consequently, all these compounds belonged to the alkaloid class. Specific interactions were studied to further understand the nature of intermolecular bonds between the most active ligands and the protein binding site residues which proved that among the constituents monoamphilectine A and Shermilamine B show more promise as Anti-TB drugs. Furthermore, the ADMET properties of these compounds or ligands showed that they have no corrosive or carcinogenic parameters. Graphical
- Open Access
A Computational Approach to Design Potential siRNA Molecules as a Prospective Tool for Silencing Nucleocapsid Phosphoprotein and Surface Glycoprotein Gene of SARS-CoV-2
An outbreak, caused by a RNA virus, SARS-CoV-2 named COVID-19 has become pandemic with a magnitude which is daunting to all public health institutions in the absence of specific antiviral treatment. Surface glycoprotein and nucleocapsid phosphoprotein are two important proteins of this virus facilitating its entry into host cell and genome replication. Small interfering RNA (siRNA) is a prospective tool of the RNA interference (RNAi) pathway for the control of human viral infections by suppressing viral gene expression through hybridization and neutralization of target complementary mRNA. So, in this study, the power of RNA interference technology was harnessed to develop siRNA molecules against specific target genes namely, nucleocapsid phosphoprotein gene and surface glycoprotein gene. Conserved sequence from 139 SARS-CoV-2 strains from around the globe was collected to construct 78 siRNA that can inactivate nucleocapsid phosphoprotein and surface glycoprotein genes. Finally, based on GC content, free energy of folding, free energy of binding, melting temperature and efficacy prediction process 8 siRNA molecules were selected which are proposed to exerts the best action. These predicted siRNAs should effectively silence the genes of SARS-CoV-2 during siRNA mediated treatment assisting in the response against SARS-CoV-2
Open AccessA Computational Approach to Design Potential siRNA Molecules as a Prospective Tool for Silencing Nucleocapsid Phosphoprotein and Surface Glycoprotein Gene of SARS-CoV-2
An outbreak, caused by a RNA virus, SARS-CoV-2 named COVID-19 has become pandemic with a magnitude which is daunting to all public health institutions in the absence of specific antiviral treatment. Surface glycoprotein and nucleocapsid phosphoprotein are two important proteins of this virus facilitating its entry into host cell and genome replication. Small interfering RNA (siRNA) is a prospective tool of the RNA interference (RNAi) pathway for the control of human viral infections by suppressing viral gene expression through hybridization and neutralization of target complementary mRNA. So, in this study, the power of RNA interference technology was harnessed to develop siRNA molecules against specific target genes namely, nucleocapsid phosphoprotein gene and surface glycoprotein gene. Conserved sequence from 139 SARS-CoV-2 strains from around the globe was collected to construct 78 siRNA that can inactivate nucleocapsid phosphoprotein and surface glycoprotein genes. Finally, based on GC content, free energy of folding, free energy of binding, melting temperature and efficacy prediction process 8 siRNA molecules were selected which are proposed to exerts the best action. These predicted siRNAs should effectively silence the genes of SARS-CoV-2 during siRNA mediated treatment assisting in the response against SARS-CoV-2
- Open Access
Combinatorial analysis of gene regulatory network reveals the causal genetic basis of breast cancer and gene-specific personalized drug treatments
Cancer is the major burden of diseases around the world. The incidence and mortality rate of cancers is mounting up with the passage of days. Breast cancer is the most demoralizing cause of death, where both diseases interlocked with each other due to some genetic, biological and behavioral motives. The molecular mechanism of breast cancer through which they crop up and manifest together remains questionable. The genetic basis of protein-protein interactions and gene networks has elucidated a group of gene regulatory systems in Breast cancer. Thus, the extraction of all genomic and proteomic data has enabled unprecedented views of gene-protein co-expression, co-regulation, and interactions in the biological system. This study explored the biological system to develop a gene-disease interaction model by implementing the extracted genomic and proteomic data of Breast cancer. The disease-specific and correlated genes were pulled out and their cabling studied by PPI, disease pathway and drug-disease interaction data to articulate their role in disease development. By analyzing mined genes that are related to breast cancer, a network model is also proposed. Exploration of all the correlated genes, Hub and common genes have given some promising pieces of evidence surrounding the genetic networking models. The result of this prospective study disclosed breast cancer mediated crosslinking or possible metastatic relation on a genetic basis. Moreover, other diseases like prostate, colorectal and ovarian cancers are at the same risk and might count into consideration. The finding provides a narrative broad approach for understanding the genetic basis of these fatal diseases by the pathway analysis with gene regulatory network evaluation.
Open AccessCombinatorial analysis of gene regulatory network reveals the causal genetic basis of breast cancer and gene-specific personalized drug treatments
Cancer is the major burden of diseases around the world. The incidence and mortality rate of cancers is mounting up with the passage of days. Breast cancer is the most demoralizing cause of death, where both diseases interlocked with each other due to some genetic, biological and behavioral motives. The molecular mechanism of breast cancer through which they crop up and manifest together remains questionable. The genetic basis of protein-protein interactions and gene networks has elucidated a group of gene regulatory systems in Breast cancer. Thus, the extraction of all genomic and proteomic data has enabled unprecedented views of gene-protein co-expression, co-regulation, and interactions in the biological system. This study explored the biological system to develop a gene-disease interaction model by implementing the extracted genomic and proteomic data of Breast cancer. The disease-specific and correlated genes were pulled out and their cabling studied by PPI, disease pathway and drug-disease interaction data to articulate their role in disease development. By analyzing mined genes that are related to breast cancer, a network model is also proposed. Exploration of all the correlated genes, Hub and common genes have given some promising pieces of evidence surrounding the genetic networking models. The result of this prospective study disclosed breast cancer mediated crosslinking or possible metastatic relation on a genetic basis. Moreover, other diseases like prostate, colorectal and ovarian cancers are at the same risk and might count into consideration. The finding provides a narrative broad approach for understanding the genetic basis of these fatal diseases by the pathway analysis with gene regulatory network evaluation.